1480 related articles for article (PubMed ID: 22204894)
1. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
Uppal L; Dhaliwal K; Butler PE
J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin A treatment of Raynaud's phenomenon: a review.
Iorio ML; Masden DL; Higgins JP
Semin Arthritis Rheum; 2012 Feb; 41(4):599-603. PubMed ID: 21868066
[TBL] [Abstract][Full Text] [Related]
9. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin type A in the treatment of Raynaud's phenomenon.
Neumeister MW
J Hand Surg Am; 2010 Dec; 35(12):2085-92. PubMed ID: 21134617
[TBL] [Abstract][Full Text] [Related]
11. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
Bello RJ; Cooney CM; Melamed E; Follmar K; Yenokyan G; Leatherman G; Shah AA; Wigley FM; Hummers LK; Lifchez SD
Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
[TBL] [Abstract][Full Text] [Related]
12. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
[TBL] [Abstract][Full Text] [Related]
13. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
Dhaliwal K; Griffin MF; Salinas S; Howell K; Denton CP; Butler PEM
Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
[TBL] [Abstract][Full Text] [Related]
14. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
15. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
Gore J; Silver R
Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
[No Abstract] [Full Text] [Related]
16. Treatment of Raynaud's phenomenon with botulinum toxin type A.
Zhang X; Hu Y; Nie Z; Song Y; Pan Y; Liu Y; Jin L
Neurol Sci; 2015 Jul; 36(7):1225-31. PubMed ID: 25616446
[TBL] [Abstract][Full Text] [Related]
17. Management of Raynaud's digital ulcer with interdigital Botulinum toxin A injection.
Navarro EP; Cañas CA; Tobón GJ
Rheumatology (Oxford); 2016 Jul; 55(7):1216. PubMed ID: 27155203
[No Abstract] [Full Text] [Related]
18. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
[TBL] [Abstract][Full Text] [Related]
19. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
20. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
